PAR 1.82% 28.0¢ paradigm biopharmaceuticals limited..

New orphan drug designation, page-15

  1. 820 Posts.
    lightbulb Created with Sketch. 328
    Mozz,
    As you alluded too the more time we get to spend in the FDA's face I think it can only help the PPS OA case. Whilst I think the PPS OA timelines are pretty set (ie we have to do the two studies etc) I do think this lifts our credability with the FDA and further derisking PAR's PPS push.
    Hopefully the strategy pays off and does not end up being another cash drag .. with another future CR required.
    DYOD

    Poolboy
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.